Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Timothy Rushmer

Anesthesiology Chico, CA Medical Doctor

NPI 1952895179 CMS profile 8797549

605 W East Ave, Chico, CA 95926

Open in the dashboard

General payments

$9,451

159 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Rushmer of Chico, CA is reported in the CMS Open Payments database as having received $9,451 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $665 36
2024 General $2,691 71
2023 General $5,009 43
2022 General $1,087 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Rushmer
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Timothy Rushmer were reported at $665. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Timothy Rushmer Anesthesiology median Middle half National median
2019 $0 $72 $23–$151 $163
2020 $0 $36 $17–$120 $114
2021 $0 $49 $21–$135 $132
2022 $1,087 $52 $22–$144 $149
2023 $5,009 $53 $23–$143 $160
2024 $2,691 $55 $25–$150 $164
2025 $665 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $3,909 53 payments
  2. Boston Scientific Corporation $1,448 31 payments
  3. Abbott Laboratories $1,172 36 payments
  4. Painteq LLC $555 2 payments
  5. Relievant Medsystems, Inc. $524 4 payments
  6. Nevro Corp. $515 6 payments
  7. Nalu Medical, Inc. $458 9 payments
  8. SPR Therapeutics, Inc $332 3 payments
  9. SI-BONE, Inc. $283 6 payments
  10. Curonix LLC $206 7 payments
  11. Other $49 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,811 146 payments
  2. Travel and Lodging $2,085 11 payments
  3. Education $555 2 payments
Products named General payments · program years 2022–2025
  1. INTELLIS ADAPTIVESTIM $2,774 38 payments
  2. RESTORESENSORSURESCAN $738 2 payments
  3. WaveWriter Alpha Prime 16 $666 10 payments
  4. Intracept Pain $566 6 payments
  5. PAINTEQ $555 2 payments
  6. Intracept Pain $524 4 payments
  7. Intracept Pain $524 4 payments
  8. Intracept Pain $524 4 payments
  9. PROCLAIM $470 16 payments
  10. Nalu Neurostimulation System $458 9 payments
  11. Other $2,887 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

790

Median for Anesthesiology: 322

Drug cost

$8,805

Median for Anesthesiology: $8,738

Branded share of claims

20.3%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 260 $2,257
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 89 $2,135
Duloxetine Hcl Generic 56 $979
Pregabalin Generic 33 $641
Lidocaine Generic 14 $635
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 56 $626
Morphine Sulfate Er Morphine Sulfate Brand 15 $312
Oxycodone Hcl Generic 14 $276
Meloxicam Generic 66 $234
Tramadol Hcl Generic 14 $202

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$624,348

Of which drugs: $4,941

Medicare patients

767

Average age 75

Services billed

9,801

466 women, 301 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 24%
Ischemic heart disease 24%
Depression 23%
Chronic kidney disease 20%
Osteoporosis 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 394 3,938 $3,026
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 23 330 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record